Biotechnology
The 2026 Nobel Prize in Medicine went to the pioneers of optogenetics. With the first optogenetic therapy approaching FDA approval and psychiatric applications in clinical trials, the prize marks a turning point for neuroscience drug development.
Biotechnology
AbbVie and Genmab's epcoritamab (Epkinly) met its primary endpoint in the Phase 3 Epcore DLBCL-2 trial, reducing disease progression or death risk by 51% compared to R-CHOP alone in newly diagnosed DLBCL. This result challenges Roche's Polivy's dominance in the first-line setting.
Biotechnology
Vaxcyte's VAX-31 met all primary endpoints in a pivotal Phase 3 trial against both Pfizer's Prevnar 20 and Merck's Capvaxive. The data are clean, the coverage is broader, and the competitive implications for the adult pneumococcal vaccine market are significant.
Biotechnology
There is a particular kind of deal that tells you something important about where a field is heading. Not the blockbuster acquisition of a late-stage asset, and not the defensive licensing of a competitor's approved drug. The kind that matters is the one where a major pharmaceutical
Pharmaceuticals
Sanofi and Regeneron announce a $1 billion expansion of their immunology alliance to develop next-generation antibodies, signaling confidence in type 2 inflammation biology despite upcoming Dupixent patent expiration.
Pharmaceuticals
A patient death and a trial amendment in Bristol Myers' Phase 3 admilparant program are raising fresh questions about liver toxicity in the LPA1R inhibitor class, just months before a pivotal readout that could reshape the IPF treatment landscape.
Biotechnology
On September 24, 2026, a panel of independent experts advising the FDA voted 7-2 that the probable benefits of Grail's Galleri multicancer early detection blood test outweigh its risks. The panel voted unanimously that the test is safe. It voted 6-4 on effectiveness. And with those
Biotechnology
Viking Therapeutics' VK2735 maintenance dosing data reveal a potential game-changer: patients can maintain 90-97% of weight loss on monthly injections instead of weekly ones. Here's what it means for the obesity drug market.
Pharmaceuticals
The FDA's approval of AbbVie's Juvmo marks the first selective D1/D5 dopamine receptor agonist for Parkinson's disease, introducing a genuinely new mechanism to a field that has relied on the same pharmacological approach for over 50 years.
Biotechnology
Celldex's barzolvolimab met all primary and secondary endpoints in Phase 3 CSU trials, demonstrating complete responses in 42-46% of patients at Week 12 and 45-54% by Week 24—establishing mast cell depletion as a genuine advance in chronic spontaneous urticaria treatment.
Biotechnology
Celldex's barzolvolimab Phase 3 data show complete response rates of 42-54% in chronic spontaneous urticaria, including patients who failed omalizumab. Here is what the mechanism means and why it matters.
Biotechnology
Alkermes' Phase 1b data for ALKS 7290, an orexin 2 receptor agonist, demonstrates the first clinical evidence that a new mechanism could transform ADHD treatment beyond traditional stimulants.